EP1858546A4 - Modified transferrin fusion proteins - Google Patents
Modified transferrin fusion proteinsInfo
- Publication number
- EP1858546A4 EP1858546A4 EP06736868A EP06736868A EP1858546A4 EP 1858546 A4 EP1858546 A4 EP 1858546A4 EP 06736868 A EP06736868 A EP 06736868A EP 06736868 A EP06736868 A EP 06736868A EP 1858546 A4 EP1858546 A4 EP 1858546A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- fusion proteins
- transferrin fusion
- modified transferrin
- modified
- proteins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65814005P | 2005-03-04 | 2005-03-04 | |
US66375705P | 2005-03-22 | 2005-03-22 | |
PCT/US2006/007617 WO2006096515A2 (en) | 2005-03-04 | 2006-03-06 | Modified transferrin fusion proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1858546A2 EP1858546A2 (en) | 2007-11-28 |
EP1858546A4 true EP1858546A4 (en) | 2009-03-04 |
Family
ID=36953883
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06736868A Withdrawn EP1858546A4 (en) | 2005-03-04 | 2006-03-06 | Modified transferrin fusion proteins |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1858546A4 (en) |
JP (1) | JP2008531059A (en) |
CA (1) | CA2599723A1 (en) |
WO (1) | WO2006096515A2 (en) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8129504B2 (en) | 2001-08-30 | 2012-03-06 | Biorexis Technology, Inc. | Oral delivery of modified transferrin fusion proteins |
CA2657277C (en) | 2006-07-13 | 2015-11-24 | Upperton Limited | Process for preparing particles of proteinaceous material |
CA2658654A1 (en) | 2006-07-24 | 2008-01-31 | Biorexis Pharmaceutical Corporation | Exendin fusion proteins |
WO2008021412A2 (en) * | 2006-08-14 | 2008-02-21 | Biorexis Pharmaceutical Corporation | Interferon beta and transferrin fusion proteins |
JP5492563B2 (en) | 2006-12-12 | 2014-05-14 | バイオレクシス ファーマシューティカル コーポレーション | Transferrin fusion protein library |
GB0711424D0 (en) * | 2007-06-13 | 2007-07-25 | Novozymes Delta Ltd | Recombinant transferrin mutants |
EP2201036A1 (en) * | 2007-08-08 | 2010-06-30 | Novozymes Biopharma DK A/S | Transferrin variants and conjugates |
CA2699916A1 (en) | 2007-09-18 | 2009-08-06 | The Jackson Laboratory | Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof |
EP3252068A3 (en) | 2009-10-12 | 2018-03-14 | Larry J. Smith | Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro |
DK2513140T3 (en) * | 2009-12-16 | 2016-01-18 | Novo Nordisk As | Double-acylated GLP-1 derivatives |
NZ724348A (en) | 2010-11-30 | 2019-12-20 | Genentech Inc | Low affinity blood brain barrier receptor antibodies and uses therefor |
DK3326620T3 (en) | 2010-12-16 | 2020-05-25 | Novo Nordisk As | SOLID COMPOSITIONS CONTAINING A GLP-1 AGONIST AND SALT OF N- (8- (2- HYDROXYBENZOYL) AMINO) CAPRYLIC ACID |
MX355361B (en) | 2011-04-12 | 2018-04-17 | Novo Nordisk As | Double-acylated glp-1 derivatives. |
JP2014132832A (en) * | 2011-05-10 | 2014-07-24 | Sekisui Chem Co Ltd | Medicament, functional food product, stabilization method of target protein, fusion protein, nucleic acid, and recombinant |
ES2779698T3 (en) | 2012-03-19 | 2020-08-18 | Brigham & Womens Hospital Inc | Growth differentiation factor 11 (GDF) for the treatment of age-related cardiovascular conditions |
HUE042757T2 (en) | 2012-03-22 | 2019-07-29 | Novo Nordisk As | Compositions comprising a delivery agent and preparation thereof |
AU2013234496B2 (en) | 2012-03-22 | 2017-07-27 | Novo Nordisk A/S | Compositions of GLP-1 peptides and preparation thereof |
ES2871328T3 (en) | 2012-06-20 | 2021-10-28 | Novo Nordisk As | Tablet formulation comprising a peptide and a delivery agent |
WO2014164981A1 (en) | 2013-03-12 | 2014-10-09 | The General Hospital Corporation | Modified mullerian inhibiting substance (mis) proteins and uses thereof for the treatment of diseases |
ES2945994T3 (en) | 2013-03-15 | 2023-07-11 | Gladiator Biosciences Inc | Gla domains as addressing agents |
EP4140497A1 (en) | 2013-04-08 | 2023-03-01 | President and Fellows of Harvard College | Compositions for rejuvenating skeletal muscle stem cells |
JP6618892B2 (en) | 2013-04-23 | 2019-12-11 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Genetic reprogramming of bacterial biofilms |
WO2014201143A1 (en) | 2013-06-11 | 2014-12-18 | President And Fellows Of Harvard College | Methods and compositions for increasing neurogenesis and angiogenesis |
CA2933335A1 (en) | 2013-12-11 | 2015-06-18 | The General Hospital Corporation | Use of mullerian inhibiting substance (mis) proteins for contraception and ovarian reserve preservation |
US10456445B2 (en) | 2014-06-02 | 2019-10-29 | Children's Medical Center Corporation | Methods and compositions for immunomodulation |
EP3280397A4 (en) * | 2015-04-06 | 2018-08-22 | President and Fellows of Harvard College | Biosynthetic amyloid-based materials displaying functional protein sequences |
EP3313875A4 (en) * | 2015-06-24 | 2018-12-26 | Board of Regents of the University of Texas System | Methods and compositions for treatment of symptoms associated with intracranial hemorrhage |
JP2018530315A (en) | 2015-08-27 | 2018-10-18 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | Compositions and methods for the treatment of pain |
US11098133B2 (en) | 2016-05-19 | 2021-08-24 | President And Fellows Of Harvard College | Methods of making gels and films using curli nanofibers |
US11459368B2 (en) | 2017-07-14 | 2022-10-04 | Livactus, Inc. | Insulin-transferrin fusion protein and its prodrug, proinsulin-transferrin, for overcoming insulin resistance |
IL275778B2 (en) | 2018-02-02 | 2023-12-01 | Novo Nordisk As | Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant |
EP3810186B1 (en) | 2018-06-21 | 2022-09-28 | Novo Nordisk A/S | Novel compounds for treatment of obesity |
WO2022008976A1 (en) | 2020-07-10 | 2022-01-13 | Institut Pasteur | Use of gdf11 to diagnose and treat anxiety and depression |
WO2022155410A1 (en) | 2021-01-15 | 2022-07-21 | President And Fellows Of Harvard College | Methods and compositions relating to anti-mfsd2a antibodies |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
WO2006017688A2 (en) * | 2004-08-03 | 2006-02-16 | Biorexis Pharmaceutical Corporation | Combination therapy using transferrin fusion proteins comprising glp-1 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5849293A (en) * | 1996-01-11 | 1998-12-15 | Cornell Research Foundation, Inc. | Use of human transferrin in controlling insulin levels |
US6458924B2 (en) * | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
-
2006
- 2006-03-06 CA CA002599723A patent/CA2599723A1/en not_active Abandoned
- 2006-03-06 WO PCT/US2006/007617 patent/WO2006096515A2/en active Application Filing
- 2006-03-06 JP JP2007558273A patent/JP2008531059A/en active Pending
- 2006-03-06 EP EP06736868A patent/EP1858546A4/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
WO2006017688A2 (en) * | 2004-08-03 | 2006-02-16 | Biorexis Pharmaceutical Corporation | Combination therapy using transferrin fusion proteins comprising glp-1 |
Also Published As
Publication number | Publication date |
---|---|
JP2008531059A (en) | 2008-08-14 |
EP1858546A2 (en) | 2007-11-28 |
WO2006096515A3 (en) | 2006-12-07 |
WO2006096515A2 (en) | 2006-09-14 |
CA2599723A1 (en) | 2006-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1858546A4 (en) | Modified transferrin fusion proteins | |
IL189246A0 (en) | Albumin fusion proteins | |
IL222924A0 (en) | Albumin fusion proteins | |
EP1934372A4 (en) | Ssb - polymerase fusion proteins | |
IL197580A0 (en) | Albumin fusion proteins | |
IL196889A0 (en) | Albumin-insulin fusion proteins | |
PL1830872T3 (en) | Fusion proteins | |
GB0426397D0 (en) | Fusion proteins | |
IL204839A0 (en) | Albumin fusion proteins | |
ZA200709871B (en) | Interferon-IgG fusion | |
ZA200901280B (en) | Exendin fusion proteins | |
EP1889908A4 (en) | Anti-cd14 antibody-fused protein | |
IL198815A0 (en) | Transferrin fusion protein libraries | |
ZA200801224B (en) | Albumin fusion proteins | |
GB0514482D0 (en) | Protein | |
EP1893635A4 (en) | Anchored transferrin fusion protein libraries | |
GB0511861D0 (en) | Proteins | |
GB0700759D0 (en) | Novel fusion protein | |
GB0522113D0 (en) | vWFA-domain containing proteins | |
GB0426399D0 (en) | Fusion proteins | |
GB0513505D0 (en) | Proteins | |
GB0514788D0 (en) | Proteins | |
GB0514481D0 (en) | Proteins | |
AU2005905300A0 (en) | Fusion Protein | |
GB0713169D0 (en) | Fusion proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20071004 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BIOREXIS PHARMACEUTICAL CORPORATION |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20090130 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 14/76 20060101ALI20090126BHEP Ipc: C12P 21/02 20060101ALI20090126BHEP Ipc: C07K 14/605 20060101ALI20090126BHEP Ipc: A61K 38/40 20060101ALI20090126BHEP Ipc: A61K 38/26 20060101ALI20090126BHEP Ipc: C12N 15/63 20060101ALI20090126BHEP Ipc: C12N 15/12 20060101AFI20090126BHEP Ipc: C12N 15/16 20060101ALI20090126BHEP Ipc: C12N 5/10 20060101ALI20090126BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20090418 |